Video

Comparing Two MPN Drugs

An expert discusses a trial comparing recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Trine Alma Knudsen, M.D., a Ph.D. student in the department of hematology at the Zealand University Hospital in Roskilde, Denmark, discusses the DALIAH trial, which compared recombinant interferon alpha-2 with hydroxyurea in patients with myeloproliferative neoplasms (MPNs).

Initially, there was a higher percentage of patients in the interferon arm who stopped treatment due to toxicities. However, after about 18 months, the researchers saw that there wasn’t much difference between the two drugs. But according to other studies, Knudsen said, staying on interferon might be worth it, as it may prove to be the superior drug after a longer time on treatment.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content